Login / Signup

Belzutifan in Individuals with von Hippel-Lindau Retinal Hemangioblastomas: Institutional Experience and Review of the Literature.

Farzad JamshidiLola LozanoBudd TuckerJean AndorfElliott SohnEdwin StoneAndrew GrovesYousef ZakhariaH Culver BoldtElaine Binkley
Published in: Ocular oncology and pathology (2024)
The drug belzutifan shows great promise for controlling RHs and preventing vision loss in patients with VHL. Further work needs to address the optimal dose, role of the drug as a neoadjuvant therapy, and long-term efficacy and tolerability of the drug in a larger cohort of patients with ocular tumors.
Keyphrases
  • adverse drug
  • rectal cancer
  • drug induced
  • emergency department
  • optical coherence tomography
  • open label
  • locally advanced
  • mesenchymal stem cells
  • smoking cessation
  • double blind